Skip to content

US · CAI · BIOTECHNOLOGY

Caris Life Sciences, Inc. (CAI) intrinsic value and stock valuation

$17.58as of 2026-11-21 · Mkt cap 6.43B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Caris Life Sciences, Inc. DCF and intrinsic value

InvestorsCraft values CAI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CAI’s statements →

Caris Life Sciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Irving, TX 75039 carislifesciences.com

How the business is doing

Fiscal 2010–2025, USD

Revenue
$812M+14.3% 5y CAGRd
20102025
Net income
-$-537.96M
20102025
Free cash flow
$66.9M
20102025
Total equity
$577.3M-3.6% 5y CAGRd
20102025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2010–2025, USD
20252024202320222020
Revenue$812M$412.3M$306.1M$258.5M$294M
Operating income$45.1M-$-257.12M-$-319.55M-$-315.76M$139.1M
Net income-$-537.96M-$-281.89M-$-341.42M-$-320.83M$27.7M
EPSd-$-1.86M-$-1.11M-$-1.34M-$-1.26M$1.54M
Operating cash flow$83.2M-$-245.2M-$-276.1M-$-285.71M$277M
Capital expenditure-$-16.26M-$-8.44M-$-22.32M-$-42.26M-$-219.45M
Free cash flow$66.9M-$-253.64M-$-298.42M-$-327.96M$57.6M
Total assets$1.13B$343.7M$412.9M$717.4M$2.61B
Total debt$379M$424.3M$217.3M$270.9M$1.75B
Net debt-$-418.81M$360.3M$160.9M$163.7M$1.69B
Total equity$577.3M-$-2.5B-$-2.14B-$-1.7B$702.2M
Cash and short-term investments$800.1M$66.2M$121.6M$409.6M$132.5M
Income statement
20252024202320222020
Revenue$812M$412.3M$306.1M$258.5M$294M
Cost of revenue$272.9M$233.5M$216.8M$178.5M$109.9M
Gross profit$539.2M$178.8M$89.3M$80M$184.2M
Research and development expenses$45.3M$113.9M$116.9M$101.3M$0.00
Selling, general and administrative expenses$392.5M$321.9M$291.5M$294.5M$27.3M
Other expenses$56.3M$130K$500K$0.00$17.8M
Operating expenses$494.1M$435.9M$408.9M$395.8M$45.1M
Cost and expenses$766.9M$669.4M$625.7M$574.2M$154.9M
Interest income$16.5M$7.12M$11.3M$950K$0.00
Interest expense$56.9M$50M$31.6M$26.7M$61.6M
Depreciation and amortization$22.6M$48.9M$49M$48.3M$110.7M
Ebitda$11.4M-$-182.95M-$-260.8M-$-245.89M$254.5M
Operating income$45.1M-$-257.12M-$-319.55M-$-315.76M$139.1M
Total other income/expenses, net-$-113.2M-$-24.77M-$-21.86M-$-5.07M-$-109.55M
Income before tax-$-68.09M-$-281.89M-$-341.42M-$-320.83M$29.5M
Income tax expense$469.9M$0.00$0.00$0.00$1.8M
Net income-$-537.96M-$-281.89M-$-341.42M-$-320.83M$27.7M
Weighted average shares outstanding$282.3M$254.7M$254.7M$254.8M$18M
Weighted average diluted shares outstanding$289.9M$254.7M$254.7M$254.8M$18M
Balance sheet
20252024202320222020
Cash and short-term investments$800.1M$66.2M$121.6M$409.6M$132.5M
Net receivables$112.1M$88.2M$55.3M$40.2M$144.3M
Inventory$0.00$39.6M$49M$47M$0.00
Total current assets$997.8M$215.7M$242.6M$516M$214.7M
Property, plant and equipment, net$63.2M$102.8M$147.5M$138.1M$1.78B
Goodwill and intangible assets$19.3M$19.3M$19.3M$19.3M$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$127.9M$128M$170.3M$201.4M$2.4B
Total assets$1.13B$343.7M$412.9M$717.4M$2.61B
Accounts payable$39.2M$27.8M$26.7M$27.3M$3.67M
Short-term debt$170K$66.2M$6.75M$57.1M$183.5M
Deferred revenue$0.00$7.47M$5.68M$1.43M$3.03M
Total current liabilities$127.1M$165.4M$95.1M$136.9M$320.3M
Long-term debt$378.8M$358.1M$210.5M$213.8M$1.56B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$421.2M$2.68B$2.46B$2.28B$1.59B
Capital lease obligations$0.00$45.1M$51M$48.5M$0.00
Total liabilities$548.4M$2.84B$2.56B$2.42B$1.91B
Common stock$280K$40K$40K$140K$0.00
Retained earnings-$-2.55B-$-2.47B-$-2.12B-$-1.68B$503.3M
Accumulated other comprehensive income (loss)$940K$210K$220K$1.7M-$-5.74M
Total equity$577.3M-$-2.5B-$-2.14B-$-1.7B$702.2M
Total investments$2.29M$2.2M$65.2M$302.4M$79M
Total debt$379M$424.3M$217.3M$270.9M$1.75B
Net debt-$-418.81M$360.3M$160.9M$163.7M$1.69B
Cash flow statement
20252024202320222020
Net income-$-68.09M-$-281.89M-$-341.42M-$-320.83M$27.7M
Depreciation and amortization$22.6M$48.9M$49M$48.3M$110.7M
Stock-based compensation$70M$18.6M$15.2M$22.9M$1.77M
Change in working capital-$-33.13M-$-29.07M-$-7.13M-$-22.26M-$-317.31M
Accounts receivable-$-29.79M-$-33.82M-$-15.08M-$-11.9M$11M
Inventory-$-20.75M$5.46M-$-4.43M-$-11.1M$0.00
Accounts payable$11M-$-230K$7.17M$8.91M$0.00
Net cash provided by operating activities$83.2M-$-245.2M-$-276.1M-$-285.71M$277M
Investments in property, plant and equipment-$-16.26M-$-8.44M-$-22.32M-$-42.26M-$-219.45M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-16.26M$52.9M$214.8M-$-282.99M-$-33.97M
Common stock issued$667.6M$0.00$0.00$0.00$160K
Common stock repurchased-$-110K$0.00$0.00$0.00-$-7.95M
Dividends paid$0.00$0.00$0.00$0.00-$-17.71M
Net cash used for financing activities$665M$200.3M$10.1M$10.5M-$-249.88M
Net change in cash$732M$8.02M-$-51.13M-$-558.25M-$-6.74M
Cash at end of period$800M$68M$60M$111.1M$66.5M
Operating cash flow$83.2M-$-245.2M-$-276.1M-$-285.71M$277M
Capital expenditure-$-16.26M-$-8.44M-$-22.32M-$-42.26M-$-219.45M
Free cash flow$66.9M-$-253.64M-$-298.42M-$-327.96M$57.6M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Caris Life Sciences, Inc.

        Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

        CEO
        David Dean Halbert
        Employees
        1.85K
        Beta
        0.68

        Explore

        Frequently asked questions

        What is the intrinsic value of Caris Life Sciences, Inc. (CAI)?

        Caris Life Sciences, Inc. (CAI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CAI undervalued?

        CAI trades at a price of $17.58 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.